ALMB-0168 is under clinical development by AlaMab Therapeutics and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I drugs for Osteosarcoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALMB-0168’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALMB-0168 is under development for the treatment of breast cancer, metastasis of the bone and osteosarcoma. It is administered through intravenous route. It acts by targeting gap junction alpha 1 protein.
AlaMab Therapeutics overview
AlaMab Therapeutics., a biotechnology company that develops therapies for spinal cord injury and breast cancer bone metastasis. The company is headquartered in United States.
For a complete picture of ALMB-0168’s drug-specific PTSR and LoA scores, buy the report here.